Article info

Original research
PI3K activation allows immune evasion by promoting an inhibitory myeloid tumor microenvironment

Authors

  • Natalie B Collins Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USADana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston Children's Hospital, Boston, Massachusetts, USA PubMed articlesGoogle scholar articles
  • Rose Al Abosy Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA PubMed articlesGoogle scholar articles
  • Brian C Miller Lineberger Comprehensive Cancer Center, Department of Medicine, Division of Oncology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA PubMed articlesGoogle scholar articles
  • Kevin Bi Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA PubMed articlesGoogle scholar articles
  • Qihong Zhao Oncology Discovery Biology, Bristol Myers Squibb, Lawrenceville, New Jersey, USA PubMed articlesGoogle scholar articles
  • Michael Quigley Research Biology, Gilead Sciences Inc, Foster City, California, USA PubMed articlesGoogle scholar articles
  • Jeffrey J Ishizuka Department of Internal Medicine (Oncology), Yale Cancer Center and Yale School of Medicine, New Haven, New Jersey, USA PubMed articlesGoogle scholar articles
  • Kathleen B Yates Broad Institute, Cambridge, Massachusetts, USACenter for Cancer Research, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts, USA PubMed articlesGoogle scholar articles
  • Hans W Pope Arsenal Biosciences, San Francisco, California, USA PubMed articlesGoogle scholar articles
  • Robert T Manguso Broad Institute, Cambridge, Massachusetts, USACenter for Cancer Research, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts, USA PubMed articlesGoogle scholar articles
  • Yashaswi Shrestha AstraZeneca, Gaithersburg, Maryland, USA PubMed articlesGoogle scholar articles
  • Marc Wadsworth Broad Institute, Cambridge, Massachusetts, USAInstitute for Medical Engineering & Science (IMES), Department of Chemistry and Koch Institute for Integrative Cancer Research, Ragon Institute, Massachusetts Institute of Technology, Cambridge, Massachusetts, USARagon Institute of MGH, MIT and Harvard, Boston, Massachusetts, USA PubMed articlesGoogle scholar articles
  • Travis Hughes Broad Institute, Cambridge, Massachusetts, USAInstitute for Medical Engineering & Science (IMES), Department of Chemistry and Koch Institute for Integrative Cancer Research, Ragon Institute, Massachusetts Institute of Technology, Cambridge, Massachusetts, USARagon Institute of MGH, MIT and Harvard, Boston, Massachusetts, USA PubMed articlesGoogle scholar articles
  • Alex K Shalek Broad Institute, Cambridge, Massachusetts, USAInstitute for Medical Engineering & Science (IMES), Department of Chemistry and Koch Institute for Integrative Cancer Research, Ragon Institute, Massachusetts Institute of Technology, Cambridge, Massachusetts, USARagon Institute of MGH, MIT and Harvard, Boston, Massachusetts, USA PubMed articlesGoogle scholar articles
  • Jesse S Boehm Broad Institute, Cambridge, Massachusetts, USA PubMed articlesGoogle scholar articles
  • William C Hahn Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USABroad Institute, Cambridge, Massachusetts, USADepartment of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA PubMed articlesGoogle scholar articles
  • John G Doench Broad Institute, Cambridge, Massachusetts, USA PubMed articlesGoogle scholar articles
  • W Nicholas Haining Arsenal Biosciences, San Francisco, California, USA PubMed articlesGoogle scholar articles
  1. Correspondence to Dr W Nicholas Haining; nhaining{at}arsenalbio.com
View Full Text

Citation

Collins NB, Al Abosy R, Miller BC, et al
PI3K activation allows immune evasion by promoting an inhibitory myeloid tumor microenvironment

Publication history

  • Accepted January 25, 2022
  • First published March 9, 2022.
Online issue publication 
March 09, 2022
  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.